ⓘ Eldelumab

                                     

ⓘ Eldelumab

Eldelumab is a fully human monoclonal antibody that targets chemokine ligand 10 /Interferon-γ-inducible protein-10 designed for the treatment of Crohns disease and ulcerative colitis.

This drug developed by Bristol-Myers Squibb and Medarex

                                     
  • PF4 CXCL9 MIG CXCL10 IP - 10 CXCL11 I - TAC Iroplact Antibodies: Eldelumab against CXCL10 CXCR4 Agonists: MIF SDF - 1 CXCL12 Ubiquitin Antagonists:
  • PF4 CXCL9 MIG CXCL10 IP - 10 CXCL11 I - TAC Iroplact Antibodies: Eldelumab against CXCL10 CXCR4 Agonists: MIF SDF - 1 CXCL12 Ubiquitin Antagonists:
  • PF4 CXCL9 MIG CXCL10 IP - 10 CXCL11 I - TAC Iroplact Antibodies: Eldelumab against CXCL10 CXCR4 Agonists: MIF SDF - 1 CXCL12 Ubiquitin Antagonists:
  • PF4 CXCL9 MIG CXCL10 IP - 10 CXCL11 I - TAC Iroplact Antibodies: Eldelumab against CXCL10 CXCR4 Agonists: MIF SDF - 1 CXCL12 Ubiquitin Antagonists:
  • PF4 CXCL9 MIG CXCL10 IP - 10 CXCL11 I - TAC Iroplact Antibodies: Eldelumab against CXCL10 CXCR4 Agonists: MIF SDF - 1 CXCL12 Ubiquitin Antagonists:
  • PF4 CXCL9 MIG CXCL10 IP - 10 CXCL11 I - TAC Iroplact Antibodies: Eldelumab against CXCL10 CXCR4 Agonists: MIF SDF - 1 CXCL12 Ubiquitin Antagonists:
  • PF4 CXCL9 MIG CXCL10 IP - 10 CXCL11 I - TAC Iroplact Antibodies: Eldelumab against CXCL10 CXCR4 Agonists: MIF SDF - 1 CXCL12 Ubiquitin Antagonists:
  • PF4 CXCL9 MIG CXCL10 IP - 10 CXCL11 I - TAC Iroplact Antibodies: Eldelumab against CXCL10 CXCR4 Agonists: MIF SDF - 1 CXCL12 Ubiquitin Antagonists:
  • PF4 CXCL9 MIG CXCL10 IP - 10 CXCL11 I - TAC Iroplact Antibodies: Eldelumab against CXCL10 CXCR4 Agonists: MIF SDF - 1 CXCL12 Ubiquitin Antagonists: